ArticleJournal of obstetrics and gynaecology of India2025
Evaluation of ProBNP and Troponin I in Cases of Placenta Accreta Spectrum Disorders and Placenta Praevia.
Article in Journal of obstetrics and gynaecology of India, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Placenta accreta spectrum (PAS) disorders and placenta praevia (PP) are major life-threatening obstetric complications. Pro-brain natriuretic peptide (ProBNP) and troponin I are circulatory biomarkers related to increased angiogenesis and tissue destruction. Aims and Objectives: The aim was to evaluate the ProBNP and troponin I levels in placenta praevia and PAS and compare their levels between cases and their corresponding matched controls in terms of age, gestational age, and BMI. Material and Methods: A case-control study was conducted over one year; ProBNP and troponin I levels were evaluated and compared in a total of 120 women enrolled, in which 30 women were of placenta praevia, 30 women were of PAS, and 60 controls (30 each) matched to corresponding controls in terms of age, gestational age, and BMI. In all recruited women, biomarker levels were detected by immunofluorescence assay method. All cases and controls were evaluated and compared in terms of demographic profile, risk factors, and maternal and perinatal outcomes. Results: In placenta praevia patients, lower mean ProBNP (0.42) and higher troponin I levels (1.58) were observed as compared to their matched controls, but this difference was not significant statistically. PAS patients had statistically significant higher mean ProBNP (1.24) as well as troponin I levels (3.84) as compared to their matched controls ( Conclusion: Both ProBNP and troponin I levels were found to be higher in cases of PAS. Troponin I had an edge over ProBNP in the identification of PAS and adverse maternal and perinatal outcomes. Both may be used as diagnostic as well as prognostic markers in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.